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Abstract
Background and Objective Irritable Bowel Syndrome
(IBS) has a substantial impact on health-related quality of
life (HR-QoL) but high-quality data pre- and post-treat-
ment using the IBS–Quality of Life (IBS-QOL) measure
are limited. The objective of this study was to evaluate the
changes from baseline of the IBS-QOL scores, symptom
scores and health economic data in IBS patients, after 4 and
8 weeks of treatment with mebeverine hydrochloride or
pinaverium bromide.
Methods This was a prospective observational cohort
study in patients with IBS, diagnosed using the Rome III
criteria in four countries (Poland, Egypt, Mexico and China).
Results A total of 607 patients were enrolled. At baseline,
the IBS-QOL total scores were 52.0 in Poland, 48.9 in
Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall.
Increases in IBS-QOL total score were statistically signif-
icant at Weeks 4 and 8 overall and in each country
(overall: 11.8 at Week 4, 24.3 at Week 8; p \ 0.001).
ClinicalTrials.gov identifier: NCT01678781.
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Improvements were shown in all IBS-QOL subscales and
scores. Symptoms and health economic outcomes were
improved. Furthermore, the favourable safety profile of
these treatments was confirmed in this study.
Conclusions This study demonstrated that IBS patients
have a substantially reduced HR-QoL and that treatment
with mebeverine hydrochloride or pinaverium bromide
improved HR-QoL.
Key Points
We performed a prospective, observational cohort
study in patients with Irritable Bowel Syndrome
(IBS), diagnosed using the Rome III criteria in four
countries (Poland, Egypt, Mexico and China)
assessing quality of life pre- and post-treatment (at 4
and 8 weeks) using the IBS-QOL measure.
Treatment with mebeverine hydrochloride in Poland,
Egypt and Mexico, and pinaverium bromide in China
confirmed treatment effectiveness in terms of
improvement in all IBS-QOL subscales and scores.
Results were statistically significant and exceeded
the minimal important response (C10.2) for the IBS-
QOL total score (change from baseline at Week 4).
At Week 8, the increase in the IBS-QOL total score
was 24.3, greatly exceeding the meaningful clinical
response (considered to be an increase of at least 14).
The favourable safety profile of treatment with either
mebeverine hydrochloride or pinaverium bromide
was confirmed in this study.
1 Introduction
Irritable Bowel Syndrome (IBS) has a substantial impact
on health-related quality of life (HR-QoL) [1, 2]. The
impact of IBS on quality of life (QOL) is often underes-
timated in patients as they do not appear to be disabled in
any obvious way and there is no apparent impact on life
expectancy [3]. QoL in IBS patients has been documented
to be even lower than QoL of diabetes mellitus, dialysis-
dependent end-stage renal disease or gastroesophageal
reflux patients [4]. As there are limited data available pre-
and post-treatment and specifically with mebeverine
hydrochloride and pinaverium bromide [5, 6], this study
was initiated to obtain QoL data in different regions of the
world, using these treatments within a single study and
using the IBS–Quality of Life (IBS-QOL) measure [7].
Mebeverine hydrochloride (Duspatal, Duspatalin,
Colofac, Colotal, Mebeverin(e-i-a), Colospa, Ruda-
kol, Boots IBS relief, Fomac, Mebecon) is a mus-
culotropic antispasmodic with a direct effect on the smooth
muscle of the gastrointestinal tract, relieving spasm without
affecting normal gut motility. Pinaverium bromide (Dice-
tel, Eldicet) is an antispasmodic that selectively acts on
the gastrointestinal tract, by inhibiting the influx of calcium
into intestinal smooth muscle cells. Both antispasmodics
are indicated for the treatment of IBS. Mebeverine
hydrochloride is a sodium channel antagonist and pinave-
rium bromide is a gastrointestinal-selective calcium chan-
nel antagonist. Both antispasmodics are available in
different dosages. In a pharmacokinetic study, the Du-
spatalin 200 mg twice-daily formulation has been com-
pared with the 135 mg tablet three times daily and has
demonstrated optimal relative bioavailability (103 % for
single and 97 % for multiple doses) [8].
The IBS-QOL measure is a specific tool developed and
validated to assess impairment of QoL in IBS [7, 9]. The
IBS-QOL measure consists of 34 IBS-specific items and a
5-point Likert scale (1 = not at all, 2 = slightly,
3 = moderately, 4 = quite a bit, 5 = extremely or a great
deal). The sum of the items is transformed into a score
(potential range 34–100; 100 = maximum QoL). The IBS-
QOL measure contains eight IBS-QOL subscales: dys-
phoria, interference with activity, body image, health
worry, food avoidance, social reaction, sexual concerns and
relationships. With regards to interpretation of results,
apart from reaching statistical significance, a minimal
important response (MIR) for the IBS-QOL measure is an
increase of 10.2 and meaningful clinical response (MCR) is
an increase of at least 14 [10].
2 Subjects and Methods
2.1 Study Design
The study was performed from July 2012 to August 2013
and took place in Poland, China, Egypt and Mexico. IBS
patients were diagnosed according to Rome III diagnostic
criteria. Patients were aged C18 years, prescribed
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mebeverine hydrochloride or pinaverium bromide accord-
ing to the local label, and provided informed consent and
written authorisation that their data could be used for
analysis. The study of either mebeverine hydrochloride or
pinaverium bromide depended on which of the medications
were marketed in the countries. The total observational
period was 8 weeks, per the US FDA guidance recom-
mendation [11]. QoL was assessed after 4 and 8 weeks of
treatment as the measure uses a recall period of the pre-
vious month (30 days).
Exclusion criteria were (i) general and specific contra-
indications to the treatment according to the local label; (ii)
being currently treated/having been treated with mebever-
ine hydrochloride or pinaverium bromide within 4 weeks
prior to study entry; (iii) pregnancy/lactation; (iv) other
conditions precluding participation (investigator judg-
ment); and (vii) previous enrolment in present study.
The study was approved by local independent ethics
committees (IECs) in China and Mexico and by a central
IEC in Poland. There was no requirement for IEC approval
in Egypt. The study was registered or approved by regu-
latory authorities as applicable, and published on Clini-
calTrials.gov on 13 July 2012 (NCT01678781).
Treatments were taken in accordance with both local
marketing authorisation and the prescribing information—
Poland: Duspatalin retard 200 mg twice daily; Egypt:
Duspatalin 135 mg three times daily; Mexico: Duspata-
lin 200 mg twice daily; and China: Dicetel 50 mg three
times daily. The Duspatalin retard 200 mg capsule for-
mulation is a prolonged-release formulation, which
explains why a twice-daily regimen is sufficient; whereas
the 135 mg tablet is an immediate-release formulation,
requiring a three-times-daily treatment regimen.
IBS-QOL questionnaires were completed electronically
by the patient at each visit using an electronic patient-
reported outcome (ePRO) instrument.
Other symptom assessments were entered directly into
the electronic case report form (eCRF).
2.2 Statistical Analysis
There were two patient samples defined for the study
analyses: a safety analysis set (SAS), consisting of all
patients who have received at least one dose of study
medication, and a full analysis set (FAS), consisting of all
patients in the SAS who had any post-baseline QoL data.
Demographic and safety analyses were carried out using
the SAS and efficacy analysis was carried out on the FAS.
Table 1 details the primary and secondary objectives of
effectiveness, assessed after 4 and 8 weeks of treatment.
Table 1 Primary and secondary objectives
Primary objective
Change from baseline in IBS-QOL total score
Secondary objectives
Changes from baseline in the 8 IBS-QOL subscales (scores)
Change from baseline in IBS-QOL total and subscale scores within patient subgroups (IBS-C, IBS-D, IBS-M, sex and age)
Change from baseline in IBS symptom score:
abdominal pain (none/mild/moderate/severe/incapacitating)
stool frequency (mean number per day during last week prior to visit)
straining (present/absent)
urgency (present/absent)
feeling of incomplete defecation (present/absent)
passage of mucus (present/absent)
bloating or feeling of abdominal distension (present/absent)







Evaluate the safety of mebeverine hydrochloride/pinaverium bromide by country and overall
IBS irritable bowel syndrome, IBS-C IBS with constipation, IBS-D IBS with diarrhoea, IBS-M IBS-mixed (constipation and diarrhoea), IBS-QOL
IBS–Quality of Life
a After 8 weeks of treatment only
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The required per-country sample size was 119 patients,
securing a comparison-wise statistical power of 95 %. This
sample size was based on the following assumptions: a
mean baseline IBS-QOL total score of 60; an MIR from
baseline[10; and a standard deviation of the change scores
of 30 [10]. To allow for dropouts, and given that this
number was an approximation, a per-country sample size
of 133 patients resulted.
Statistical analysis of changes from baseline in total
scores and subscores was performed using the Wilcoxon
signed–rank test. A p value \0.05 was considered statis-
tically significant.
3 Results
3.1 Disposition and Demographics
All patients (n = 607) received at least one dose of study
drug and were included in the SAS. A total of 596/607
patients (98.2 %) had post-baseline QoL data—the FAS.
Per country, the FAS consisted of: Poland—133 patients,
99.3 %; Egypt—208 patients, 99.5 %; Mexico—120
patients, 99.2 %; and China—135 patients, 94.4 %.
Figure 1 shows patient disposition and Table 2 sum-
marises the demographic data.
Patients in Poland, Egypt and Mexico received treat-
ment with mebeverine hydrochloride and patients in China
received treatment with pinaverium bromide. Overall,
464/607 patients (76.4 %) received mebeverine and
143/607 patients (23.6 %) received pinaverium.
A total of 259 (42.7 %) patients reported taking con-
comitant medication at the start of or during the study.
Concomitant medication was indicated for both IBS and
other conditions.
With regards to IBS subgroups, the IBS with constipa-
tion (IBS-C) subgroup was far more prevalent in Mexico
and the IBS with diarrhoea (IBS-D) subgroup was far more
prevalent in China.
3.2 Primary Objective
3.2.1 Change from Baseline in Irritable Bowel Syndrome
(IBS)–Quality of Life (IBS-QOL) Total Score
Table 3 provides an overview of the mean IBS-QOL total
score at baseline, after 4 and 8 weeks, as well as the sta-
tistical analyses of the primary objective of the change
from baseline in IBS QOL total score at Weeks 4 and 8
(FAS).
At baseline, the IBS-QOL mean total scores were sim-
ilar and ranged from 48.9 to 52.0 but China had a signifi-
cantly higher score of 76.4. Statistical analysis of the
primary objective of IBS-QOL total score showed a sta-
tistically significant increase from baseline at Week 4
and 8, in each country and overall. The mean increase from
baseline was greater at Week 8 (overall 24.3; range by
country 10.4–31.8) than Week 4 (overall 11.8; range by
country 7.7–14.9). For each country the increase at Week 8
was greater than at Week 4.
3.3 Secondary Objectives
3.3.1 Change from Baseline in IBS-QOL Subscales
Figure 2 displays and Table 4 summarises the results
regarding the IBS subscales (per country and overall,
respectively).
There was a statistically significant increase from
baseline in IBS-QOL for all subscales at Week 4 and 8,
overall. Also, for each country, there was a statistically
significant increase at Week 4 and 8, with the exception of
interference with activity and social reaction in Mexico at
Week 4 only. At Week 4, the increases for subscales for
health worry, dysphoria, food avoidance and body image
exceeded the MIR, whereas for social reaction and
Enrolled:
Poland (n = 134)
Egypt (n = 209)
Mexico (n = 121)
China (n = 143)
Overall: (n = 607)
Discontinued from study:
Poland: (n = 2) - 1.5%: withdrawal by patient (n=2)
Egypt: (n = 1) - 0.5%: adverse event (n=1)
Mexico: (n = 0)
China: (n = 21) - 14.7%:
lack of efficacy (n = 3)
withdrawal by patient (n = 3)
lost to follow-up (n = 7) 
recovery (n = 8)
Overall: (n = 24) 4.0%:
adverse event (n = 1)
lack of efficacy (n = 3)
withdrawal by patient (n = 5)
lost to follow-up (n = 7)
recovery (n = 8)
Completed Study:
Poland (n = 132) 98.5%
Egypt (n = 208) 99.5%
Mexico (n = 121) 100%
China (n = 122) 85.3%
Overall: (n = 583) 96.0%
Fig. 1 Patient disposition (all patients)
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Table 2 Summary of demographic data by country and overall (safety analysis set)
Characteristic Poland Egypt Mexico China Overall
(n = 134) (n = 209) (n = 121) (n = 143) (n = 607)
Sex [n (%)]
Male 47 (35.1) 99 (47.4) 25 (20.7) 74 (51.7) 245 (40.4)
Female 87 (64.9) 110 (52.6) 96 (79.3) 69 (48.3) 362 (59.6)
Race [n (%)]
Asian 0 0 0 143 143 (23.6)
Black 0 3 (1.4) 0 (100.0) 3 (0.5)
White 134 (100.0) 0 15 (12.5) 0 149 (24.6)
Other 0 206 (98.6) 105 (87.5) 0 311 (51.3)
Unknown 0 0 1 0 1
Age (n) 134 209 120 143 606
Mean (SD) [years] 43.8 (14.30) 37.2 (10.76) 44.4 (15.36) 43.6 (13.94) 41.6 (13.68)
Minimum, maximum (years) 20, 74 19, 75 19, 78 20, 80 19, 80
Age group [n (%)]
18–30 years 26 (19.4) 69 (33.0) 26 (21.7) 27 (18.9) 148 (24.4)
31–40 years 36 (26.9) 58 (27.8) 30 (25.0) 42 (29.4) 166 (27.4)
41–65 years 63 (47.0) 81 (38.8) 49 (40.8) 66 (46.2) 259 (42.7)
[65 years 9 (6.7) 1 (0.5) 15 (12.5) 8 (5.6) 33 (5.4)
Out of range/missing age 0 0 1 0 1
Subgroup of IBS [n (%)]
IBS-C 21 (15.7) 55 (26.3) 77 (64.2) 20 (14.0) 173 (28.5)
IBS-D 70 (52.2) 62 (29.7) 23 (19.2) 97 (67.8) 252 (41.6)
IBS-M 43 (32.1) 92 (44.0) 20 (16.7) 26 (18.2) 181 (29.9)
Unknown 0 0 1 0 1
Percentages are based on the number of patients with non-missing data in the respective group
IBS irritable bowel syndrome, IBS-C IBS with constipation, IBS-D IBS with diarrhoea, IBS-M IBS—mixed (constipation and diarrhoea), SD
standard deviation
Table 3 Statistical analyses of the primary objective of the change from baseline in the Irritable Bowel Syndrome–Quality of Life (IBS-QOL)
total score at Weeks 4 and 8
Visit IBS-QOL total scorea
Poland Egypt Mexico China Overall


















































Data are presented as mean (standard deviation)
IBS-QOL Irritable Bowel Syndrome-Quality of Life, QoL quality of life, *p \ 0.001, **p = 0.001
a Scale: 100 = best possible QOL, 0 = worst possible QoL
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Fig. 2 Change from baseline,
in Irritable Bowel Syndrome–
Quality of Life (IBS-QOL)
subscale scores at Weeks 4 and
8 in Poland (a), China (b),
Egypt (c) and Mexico (d)
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***:  p < 0.001; *: p < 0.05 
Fig. 2 continued
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interference with activity and relationships, the increases
were just below the MIR at 10.0 or 10.1. For sexual con-
cerns, the increase was lower at 8.4. For each subscale,
overall and in each country, the mean increase at Week 8
was greater than at Week 4.
Patients in Poland, Egypt and Mexico had similar mean
baseline scores for the subscales and responses in Poland
and Egypt at Week 4 were comparable, whereas in Mexico
all mean responses, with the exception of ‘body image’ and
‘sexual’, were lower. By Week 8, the mean response for
patients in Poland, Egypt and Mexico was similar. In
China, the patients had higher baseline subscale scores and
response at Week 4 and Week 8 was less than in the other
countries, which was most apparent for ‘body image’ and
‘relationships’.
3.4 Analysis of IBS Subgroups
There was a mean increase from baseline in IBS-QOL total
and subscales for all IBS subgroups at Weeks 4 and 8. For
each total score and subscale, overall and in each country,
the increase at Week 8 was greater than at Week 4. The
response in patients with IBS-D at both Week 4 and 8 was
lower than for patients with IBS-C and irritable bowel
syndrome—mixed (constipation and diarrhoea) (IBS-M),
suggesting that patients with IBS-D respond less well to
treatment than those with IBS-C and IBS-M. Lower
responses were seen for the IBS subgroups in Mexico at
Week 4 (as for all IBS patients combined), with the
response for IBS-C patients and particularly IBS-D patients
being lower there than those patient subgroups in Poland
Table 4 Statistical analyses of the secondary endpoint of the change from baseline, overall, in Irritable Bowel Syndrome–Quality of Life
subscale scores at Weeks 4 and 8




































































































Data are presented as mean (standard deviation)
IBS-QOL Irritable Bowel Syndrome–Quality Of Life, QoL quality of life, *p \ 0.001
a Scale: 100 = best possible QoL, 0 = worst possible QoL
Table 5 Irritable bowel syndrome symptom scores for abdominal pain/discomfort at baseline and after 4 and 8 weeks of treatment with
mebeverine hydrochloride or pinaverium bromide by country and overall
Visit Mean abdominal pain/discomfort: IBS symptom scoresa
Poland (n = 133) Egypt (n = 208) Mexico (n = 120) China (n = 135) Overall (n = 596)






























Data are presented as mean (standard deviation)
IBS irritable bowel syndrome
a Scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = incapacitating
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and Egypt. In China, the IBS-QOL total score for each IBS
subgroup showed a higher baseline and response was lower
at Weeks 4 and 8. Evaluation of the subscales showed
responses for IBS-D patients being consistently lower than
for IBS-C and IBS-M patients.
3.5 Analysis by Sex and Age
There was no notable difference according to sex regarding
the increase in IBS-QOL total scores at Week 4 and 8.
Females had slightly lower mean baseline IBS-QOL total
scores and showed a greater mean increase from baseline
than males at Week 8 in all countries with the exception of
Egypt. There was no apparent difference in response with
increasing age.
3.6 IBS and Gastrointestinal Symptom Scores
Table 5 summarises the IBS symptom scores for abdomi-
nal pain and discomfort.
There was a mean decrease in abdominal discomfort/
pain at Week 4 and a further decrease at Week 8 in all
countries (overall: -0.9 at Week 4 compared with -1.3 at
Week 8).
Analysis of IBS-C and IBS-D subgroups showed
improvements for both stool frequency and stool form.
Overall for IBS-C, there was a mean increase from baseline
of 0.4 per day for stool frequency at Weeks 4 and 8 and a
mean increase in stool form of 0.6 (Week 4) and 0.7
(Week 8). Overall for IBS-D, there was a mean decrease at
Weeks 4 and 8 (-0.9 and -1.2 per day, respectively) for
stool frequency and for stool form of -1.4 (Week 4) and
-1.6 (Week 8).
Overall, patients showed consistent improvement across
the IBS symptoms of straining, urgency, feeling of
incomplete defecation, passage of mucus and bloating/
feeling of abdominal distension. These symptoms were
present in 41.6–79.9 % of patients at baseline; they showed
an improvement in 26.1–36.6 % of patients at Week 4 and
in 37.2–47.4 % of patients at Week 8. For the IBS sub-
groups, 87.2 % of IBS-C patients experienced bloating or a
feeling of abdominal distension at baseline and showed a
notable improvement from Week 4 to Week 8 (26.3 to
55.9 % of patients) and for IBS-D patients, 75.2 % of
patients had a feeling of urgency at baseline, which showed
the most improvement compared to other IBS symptoms at
both Week 4 and Week 8 (47.7 and 59.3 % of patients,
respectively). Bloating/abdominal distension is a symptom
that is typically reported in the Asian population, and
described in Asian consensus guidelines as being one of the
most predominant symptoms of IBS. However, within the
Rome III diagnostic criteria, there is no mention of bloat-
ing; therefore, it is of interest to have data on improvement
of symptoms of bloating/abdominal distension with treat-
ment on top of data regarding the QoL.
There was a mean decrease from baseline for all gas-
trointestinal symptoms (number of occurrences during the
last week prior to visit): heartburn (-0.5), early satiety
(-0.7), postprandial fullness (-0.8), nausea (-0.5) and
vomiting (-0.2) at Week 4. For heartburn, early satiety
and postprandial fullness, there was a greater decrease from
baseline at Week 8 (means of -0.7, -1.0 and -1.2,
respectively), whereas for nausea and vomiting there was
no further change at Week 8 versus Week 4.
3.7 Health Economic Data
The health economic data showed that no patients spent
any days in hospital due to their IBS in the 8-week treat-
ment period, compared to a mean of 0.2 days (patients in
Egypt, Mexico and China only) in the 8-week period prior
to baseline. For the patients currently employed, a mean of
0.1 days (patients in Poland, Egypt and China only) was
missed from work during the 8 weeks of treatment due to
IBS, compared with a mean of 1.2 days (patients in all
countries) in the 8-week period prior to baseline.
3.8 Safety
Treatment was well-tolerated. The incidence of adverse
events (AEs) was low (3.3 % of patients), the most fre-
quently reported being headache (three patients) and
pharyngitis and upper respiratory tract infection (in two
patients each). Twenty patients reported a total of 21 AEs.
Two AEs considered possibly drug-related were abdominal
distension (moderate severity) and somnolence (mild
severity), both of which were non-serious and ongoing at
the end of the study period; both occurred with mebever-
ine. The other 19 AEs were considered unrelated to study
treatment. A serious AE of mild haemorrhoids (requiring
hospitalization for surgery) was not considered drug-rela-
ted by the investigator (in China). A pregnancy was
reported after the start of the study, which is currently
ongoing (in Egypt).
4 Discussion
The IBS-QOL [7] questionnaire was developed by Patrick
and Drossman [7] in the 1990s and further validation has
confirmed the responsiveness of the scale [1, 10, 2]. A
systematic review has appraised the IBS-QOL measure as
the best of five IBS-specific QoL scores available and
assessed to establish changes in HR-QoL [12].
This study (596 IBS patients, 59.6 % females, assessed
using the Rome III criteria) shows a mean, overall IBS-
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QOL total score at baseline of 56.4, indicative of moderate/
severe disease and is consistent with an international sur-
vey of patients with IBS published by Drossman et al. in
2009, where patients also met Rome III criteria for IBS in
90.8 % of the cases (1,966 patients; 83 % female, 91 %
Caucasian, 78 % USA/Canada) [2] and where the overall
mean at baseline was 51.1.
In this study, the impairment at baseline was similar in
Egypt, Mexico and Poland (mean IBS-QOL total scores of
48.9–52.0), but lower in China at 76.4 (indicative of mild/
moderate disease). Of note, there are no general practitio-
ners in China and patients consult specialist care immedi-
ately, which potentially explains severity of disease being
less in China at baseline; thereby leaving a smaller relative
room for improvement. Previous studies have shown dif-
ferent mean baseline IBS-QOL total scores, using different
diagnostic criteria, a different male/female ratio, different
IBS subtyping distribution and different geographical
locations: 70.3 (30 Japanese patients, percentage females/
males not stated, Rome II diagnosis) [3]; 66.3
(1,555 patients in Canada, 85.1 % females, physician
diagnosed) [13]; and 64.3 (value adjusted for age, educa-
tion, race, marital status) (317 patients in Canada, 100 %
females, Rome I diagnosis) [10]. These differences may
reflect known cross-cultural differences across countries
(e.g. race, food or lifestyle) and variation in diagnosis and
sex of patients. In this study, all patients were diagnosed
according to the Rome III criteria, so the diagnosis of IBS
(Rome III) is not a contributory factor to the higher base-
line seen in China.
For the IBS-QOL, Drossman et al. [10] reported an MIR
to be an increase of 10.2 and an MCR to be an increa-
se C14. In this study, the overall change from baseline in
IBS-QOL total score at Week 4 of 11.8 achieved the MIR
and by Week 8 the improvement of 24.3 greatly exceeded
the MCR.
In this study, the greatest impairment at baseline
(determined as scores \55) was observed for the subscale
of food avoidance (43.7), health worry (51.8), dysphoria
(53.0) and interference with activity (54.4). These findings
were similar to the previously mentioned international
survey results [2], where the greatest impairments of sim-
ilar magnitude were shown for food avoidance, dysphoria
and interference with activity, but not health worry. In
Japanese patients [3], food avoidance, dysphoria and
interference with activity also showed the greatest
impairment. Studies in Canada showed the greatest base-
line impairment in food avoidance, health worry and body
image [13], and for food avoidance, interference with
activities and dysphoria [10].
The greatest improvements in IBS-QOL in this study,
after 8 weeks of treatment, were observed for the subscales
of food avoidance, health worry, dysphoria and
interference with activity; with these subscales having the
lowest pre-treatment scores, they have a greater potential
for improvement. Similar findings to this study have been
previously reported [2], with the exception of social reac-
tion also having a greater improvement and replacing food
avoidance. The remaining subscales of body image, social
reaction, sexual concerns and relationships in this study all
showed clinically meaningful responses at 8 weeks (range
17.4–28.9).
Randomised placebo-controlled trials conducted in
patients with IBS tend to be characterised by a relatively
high placebo response. Considering the fact that a placebo
effect generally tends to occur early in treatment and is less
likely to persist, and the IBS-QOL scores increasing up to
Week 8, this does not appear to have significantly impacted
the outcome of the study; albeit a certain degree of placebo
response cannot be completely excluded. Patel et al. [14]
have demonstrated that fulfilment of the Rome criteria for
study entry and an increased number of office visits are
significantly associated with a lower placebo response rate.
By requiring patients to fulfil the Rome III criteria, and by
having three visits within the 8-week treatment period, a
proactive effort was made to contribute to a lower placebo
response rate.
Abdominal pain is one of the main symptoms associated
with IBS and a responder has been defined in several
studies in IBS patients [15] as demonstrating a 50 %
decrease in symptom severity. For the IBS symptoms of
abdominal pain and discomfort in this study, a mean
decrease of [50 % in symptom severity was seen in all
countries, and overall, at Week 8.
This study provides further relevant information on the
IBS-QOL measure as a means to determine adequate
treatment response. For the clinician, the study attests to
the value of the IBS-QOL as a ‘barometer’ of the patient’s
clinical course, more than any biological measure. It pro-
vides information on the patient’s perception of ill health,
and how it is modified for better or worse in response to
treatment, and can therefore be used as a yardstick of
treatment progress, including when a particular interven-
tion would be considered optimal.
The limitations of this study are in regard to both the
study being observational in design and also to how the
findings can be related to other populations. An observa-
tional study represents a ‘less perfect’ experiment than an
efficacy trial and there can be issues relating to data quality
and completeness, as well as the non-randomised design.
The aim of this study, however, was to provide high-
quality data by gathering it electronically, and statistical
analysis showed significant increases from baseline in IBS-
QOL total score at Weeks 4 and 8 for all countries and
overall, which could be quantified in terms of a high MCR
at Week 8. The findings, however, may not be applicable to
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men or women with milder or more severe disease, or with
other functional gastrointestinal symptoms. The study does
provide new information regarding the impact of IBS on
HR-QoL and the magnitude of improvement in response to
treatment with mebeverine hydrochloride or pinaverium
bromide, showing the effectiveness of these treatments in a
real-life setting. Many patients in this observational study
received treatment for IBS and then in addition received
mebeverine hydrochloride or pinaverium bromide, reflec-
tive of the real-life setting (where often a combination of
medications is given to address the symptoms of the indi-
vidual patient and IBS subtype) and showing the added
value of additional treatment.
5 Conclusion
Treatment of patients with IBS with mebeverine hydro-
chloride in Poland, Egypt and Mexico and pinaverium
bromide in China confirmed the effectiveness of the study
medication in terms of the improvement in IBS-QOL total
scores and subscales. Results were statistically significant
and exceeded the MIR (C10.2) for the IBS-QOL measure,
from baseline, with the changes being greater at Week 8
than Week 4. At Week 8, the increase in the IBS-QOL
total score was 24.3, greatly exceeding the MCR (consid-
ered to be an increase of at least 14) [10].
An improvement in IBS and gastrointestinal symptoms
was also shown for the patients overall and for each sub-
group (IBS-C, IBS-D and IBS-M). There was also an
improvement in the health economic data for the patients,
with a reduction during the treatment period in both the
number of days spent in hospital and the number of days
missed from work. Furthermore, the favourable safety
profile of these treatments was confirmed in this study.
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